MED-LATANOPROST SOLUTION

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

LATANOPROST

Tilgjengelig fra:

GENERIC MEDICAL PARTNERS INC

ATC-kode:

S01EE01

INN (International Name):

LATANOPROST

Dosering :

50MCG

Legemiddelform:

SOLUTION

Sammensetning:

LATANOPROST 50MCG

Administreringsrute:

OPHTHALMIC

Enheter i pakken:

2.5ML/5ML

Resept typen:

Prescription

Terapeutisk område:

PROSTAGLANDIN ANALOGS

Produkt oppsummering:

Active ingredient group (AIG) number: 0132916002; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2014-07-30

Preparatomtale

_Page 1 of 28_
_MED-LATANOPROST (Latanoprost)_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MED-LATANOPROST
Latanoprost ophthalmic
solution
Solution, 50 mcg/mL, Ophthalmic
Prostaglandin F
2α
analogue
Generic Medical Partners Inc.
251 Consumers Road Suite 1200
Toronto, Ontario
M2J 4R3
Date of Initial Authorization:
June 25, 2014
Date of Revision:
July 27, 2023
Submission Control Number: 273339
_Page 2 of 28_
_MED-LATANOPROST (Latanoprost)_
_ _
RECENT MAJOR LABEL CHANGES
None at the time of most recent authorization
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
4
4.1
Dosing Considerations
...............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
......................................................... 4
4.4
Administration
..........................................................................................................
5
4.5
Missed Dose
........................................